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Despite overall improvements in the
prognosis for childhood malignancies children
with· primary metastatic or relapsed tumours
are not likely to be cured with a conventional
combined therapy. In such patients, the EFS
rate at 3yrs remains less than 30%. Solid
tumours in children, such as neuroblastoma,
rhabdomyosarcoma, Ewing's tumour, Wilm's
tumour and germ cell tumour are all
chemotherapy sensitive and exhibit a dose-
response relationship to therapy with selected
agents like alkylating agents, irradiation,
anthracyclines, vinca alkaloids, anti-
metabolites and topoisomerase inhibitors [1].
For agents whose major dose limiting toxicity is
myelosuppression, haematopoietic stem cell
(HSC) rescue may permit 3-10x dose
escalation before nonhaematopoietic toxicity
becomes dose limiting and combination of
three or more non-cross resistant drugs at full
or nearly full doses has a curative potential.
Therefore, several groups have developed
regimens to exploit the steep dose response
curves by using stem cell rescue to circumvent
the dose-limiting haematopoietic toxicity.
NEUROBLASTOMA
Neuroblastoma (NBL) is the commonest and
best studied pediatric solid tumours. This
disease is a particulary good candidate for
high dose strategies: it is sensitive to
chemotherapy and radiation and for most
patients present with a disseminated disease
for which conventional chemotherapy
produces less than a 20% chance for a long
term survival. However, only two randomized
studies have been reported so far. The study
by Pinkerton et al. demonstrated an advantage
of consolidation with high dose melphalan and
bone marrow rescue over no further therapy
[2]. The Children's Cancer Group has made a
large randomized comparison of high dose
carboplatin-melphalan-VP16 and total body
irradiation (TBI) with autologous, purged bone
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marrow (BM) rescue as consolidation vs. no
further therapy in children with high risk
neuroblastoma. All patients who completed
cytotoxic therapy without disease progression
were then randomly assigned to receive no
further therapy or treatment with 13-cis-retinoic
acid for six months. The final analysis has
demonstrated a significantly better event-free
survival (EFS) in children who received high
dose therapy (HDT) [3]. In the second
randomization, the group treated with 13-cis
fared better than pts with no further therapy.
The most significant difference was that
between patients (pts) with HOT and retinoic
acid vs. conventional chemotherapy (only -
55% vs. 18% EFS-rate). This randomized
study demonstrates for the first time that HOT
is beneficial for patients with NBL, and that
additional therapy with retinoic acid further
improves survival.
Many cooperative groups carried out several
non-randomized trials. Their results must be
regarded as suggestive rather than definitive
since without randomization, unknown
selection factors may bias the comparison. The
results of these small studies differed
sigificantly. McCowage reported an EFS rate of
87% at 5 yrs in 28 children older than 1 yr of
age, and Stage IV NBL treated with teniposide,
melpahalan, cisplatin and TBI with non-purged
BM reinfusion as rescue [4]. Dini et al.
achieved a 29% progression-free survival rate
in 34 patients (aged 1-7 yrs) with resistant or
relapsed and primary metastatic NBL treated
with a regimen including vincristine,
fractionated TBI and melphalan. Unpurged BM
was used as rescue [5]. Since many biological
and other therapy related factors may
influence the prognosis, it is not possible to
draw a definitive conclusion from these
studies.
The European Group for Blood and Marrow
Transplant Registry provides sufficient data in
order to evaluate the survival of a large cohort
of children with NBL who were treated with
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HOT at different European centers. Even
though treatment modalities differed between
centers and countries, the large number of
patients included in the analysis partially
compensated for this disadvantage.
Philip et al. reported on 1070 myeloablative
procedures followed by stem cell rescue as
either BM or PBSC [6]. The overall survival
(OS) was 49 % at 3 yrs, and 33% at 5 yrs,
which confirmed previous findings that HOT
shifts the survival curve to the right, Le.
prolongs survival without a significant effect on
the definitive cure rate. It is worth noting that
the matched pair comparison of 17 allogeneic
and 34 autologous transplantation did not
reveal any difference. Persisting bone (99Tc
and lor mlBG scan positive) and bone marrow
involvement after induction treatment were the
major negative prognostic factors [7]. There
was no difference between high dose therapy
incorporating TBI and chemotherapy alone.
There was no significant difference in
prognosis between single and double HOT.
A French group conducted a nonrandomized
pilot study (LMCE2) using a double
harvest/double graft approach with two
different HOT regimens: tenoposid,
carmustine, cisplatinum (or carboplatin), and
vincristin, melphalan and TBI. The first harvest
was scheduled 4 weeks after the last
chemotherapy, the second one 60-90 days
after HOT. The marrow was purged in vitro by
an immunomagnetic technique. The OS values
at 2 yrs and 5 yrs were 36% and 32%
respectively. The toxic rate was very high at
24%, which was probably due to the delayed
engraftement related in part to the BM-
harvesting after 1. HOC [8]. In the subsequent
study of this group (LMCE3), a HOT
(vincristine, melphalan and fractionated TBI)
was given as consolidation in pts who were in
complete remission after induction therapy.
Purged BM was used as rescue. The
progression-free survival rate was 29% at 7 yrs
[9]. Oata derived from two concurrent
Children's Cancer Group Studies suggested
that consolidation with myeloablative
chemoradiotherapy and autologous BMT was
more effective than continued multiple courses
of chemotherapy, especially in patients with
MYCN amplified neuroblastoma. EFS rate for
patients with MYCN amplified tumours was
67% [10]. The results published by Kawa et al.
also indicate an advantage for HOT only in pts
who have MYCN amplified tumours [11].
These data point to the need to identify
subgroups, since the relative efficacy of
myeloablative and non-myeloablative therapy
may vary, depending on the biological
characteristic of the tumour SUbgroup.
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There is a small but very promising single
institution study published by Klingebiel et al.
[12]. The patients were treated according
to the German Neuroblastoma Trial NB 90
and then consolidated with [131 l-m]IBG
(0.58 GBq/kg) prior to the HOT, which
consisted of melphalan, carboplatin and
etoposide. The rescue consisted of highly
purified autologous peripheral progenitor cells.
After haematopoietic reconstitution
immuntherapy with anti-G02 murin or chimeric
antibodies (ch14.18) was administered. Nine
out of eleven children are alive disease free
with a median observation time of 19 months.
An important contribution to the assessment
of the role of HOT in pts with NBL is the analysis
of the German NBL 90 Study. Patients with
Stage IV NB received either HOT (melphalan,
etoposide, carboplatin) or twelve alternating
cycles of oral melphalan/etoposide and oral
cyclophosphamide and vincristine. Forty - three
pts received HOT and 68 were on maintanance
therapy. The progression-free survival (PFS)
was 30% for the group of patients (68 pts)
receiving maintenance therapy, compared with
27% for the HOT group (43 pts) [13].
It seems that HOT might be beneficial for
selected patients with NBL (older than 2 yrs,
MYCN amplified tumours), but the timing, type
of conditioning and of rescue important for
definitive cure remain to be defined.
EWING'S FAMILY OF TUMOURS
Ewing's tumors (Ewing's sarcoma and
peripheral neuroectodermal tumour) are
sensitive to radio- and chemotherapy.
However, patients with bone and bone marrow
metastases, pelvis primary and early relapse
have a dismal prognosis. In these patients, the
dose escalation was thought to improve
prognosis. Unfortunately, no randomized trial
has been conducted so far. Several studies on
small series of patients have been published.
Burdach et al. reported on a group of 17
patients with metastatic or relapsed Ewing's
sarcoma, who were treated with
hyperfractionated TBI and HOT consisting of
melphalan and etoposide with or without
carboplatin [14]. The probability of a relapse at
6 yrs was 52%. However, these very good
results have not been confirmed by
subsequent trials. Laws et al. reported 6 yrs
later on 25 patients with poor prognosis EWing'
sarcoma, who were treated with similar HOT
(TBI followed by melphalan and etoposide).
The EFS-rate was 34%. The patients received
IL2 as immunmodulation after HOT [15]. The
analysis of 171 pts with primary metastatic
Ewing's tumour treated according to the
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EICESS studies revealed, however, that in pts
with combined lung and skeletal metastases, a
consolidation with HOT and/or whole lung
irradiation improved EFS from 0% to 27% [16].
The French Society of Pediatric Oncology
(SFOP) examined the efficacy of busulfan and
melphalan given as a consolidation to patients
with metastatic Ewing's sarcomas. The EFS
and overall survival (OS) rate at 3 yrs were
52% and 76%, resepectively. These results
compared favourably with those observed after
treatment with conventional chemotherapy
alone [17]. The National Cancer Institute
conducted three trials (1981 until 1986), which
were designed to determine whether TBI
administered as consolidation therapy would
improve the prognosis in high risk Ewing's
sarcoma patients. With a minimum follow-up of
6 yrs, it has become clear that this approach
has not improved the prognosis in this group of
patients [18].
The retrospective multivariate analysis of the
data from the registry of the EBMT Solid
Tumour Working Party revealed several
important facts concerning HOT in Ewing'
tumours [19]. The OS in 411 patients
registered was 30%. In 219 pts, the data were
complete so a multivariate analysis was
performed. The group who received a busulfan
containing regimen had a superior OS rate of
41 % in comparison with the group who
received a TBI containing regimen (14%). A
matched pair analysis based on primary
tumour sites, type of metastases at diagnosis,
status prior to HOT and organs involved at
HOT comparing TBI versus busulfan regimens
was in favour of busulfan regimens (OS at 5
yrs BU 28% versus TB111%, p=0.04).
Based on these results, busulfan and
melphalan containing HOC will be examined in
a randomized fashion in the new Euro-
E.W.I.N.G.99 protocol.
RHABDOMYOSARCOMA
The prognosis of patients with localised
tumours treated according to the cooperative
studies in Europe and USA has improved in
the last 20 years, with survival rates of
approximately 70%: In contrast, the chance of
cure in primary metastatic or relapsed tumours
is very poor [20,21]. The prognostic relevant
factors in pts with primary metastatic tumors
treated according to the CWS-Studies -81, -86
and -91 were: 1. age ( >10 yrs), 2. alveolar
histology, 3. more than one metastatic site
and/or bone/bone marrow metastases. Pts with
Stage IV and no risk factors had an EFS rate
at 5 yrs of 31 %, with one risk factor 22% and
with >2 risk factors 2% (p<O.OOO). Since RMS
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is a chemosensitive tumour the escalation of
dose intensity seemed to be the best way of
improving the results.
A retrospective analysis of the
German/Austrian Pediatric Bone Marrow
Transplantation Group Registry revealed 36
pts with primary metastatic or relapsed
rhabdomyosarcoma (RMS) who were given
HOC±TBI and HR rescue [21]. Primary therapy
was given according to CWS-Studies or the
European MMT Stage IV Study. The HOT
consisted of fractionated melphalan 4x 30-
45mg/m2 , etoposide 40-60mg/kg, carboplatin 3
x 400-500 mg/m2 in 26 pts. 10 pts received
additional fractionated TBI. Seven pts were
treated with melphalan alone or in combination
with carboplatin. Two patients received
cyclophosphamide/busulfan with TLI (total
lymphoid irradiation) and 1 cyclophosphamide
with FTBI. Thirty - three patients were given
autologous BM or peripheral blood stem cells
(PBSC) as hematopoietic rescue and five were
given allogeneic bone marrow. Ten patients
received adjuvant IL2. There was one toxic
HOC-related death. Ten patients were alive
free of disease with a median observation time
of 43 months (23-92), and two patients were
alive with evidence of the disease. The tumour
recurred in the majority of patients at
previously known sites, in 5 cases new
metastatic sites were observed. The patients
with primary localised tut:nours who had been
treated with HOT because of a relapse did
better (4 of 9 alive disease free) than patients
with primary metastatic disease (5 of 27 alive
disease free). This analysis did not show any
benefit from HOT, as late consolidation after
standard chemotherapy and local therapy in
pts with poor risk RMS.
In the European MMT Stage IV Study 52 of
175 eligible pts with Stage IV RMS received
melphalan as a late consolidation after
achieving CR. The respective 3 yrs EFS and
OS rate were 29.7% and 40%, compared with
19.2% and 27.7, in those receiving standard
chemotherapy [22].
The analysis of pts with RMS registered in
the EBMT registry provides information on
HOT with HR administered by several
investigators participating in the EBMT group
for children and young adults with RMS [23,
24, 25, 26]: 418 pts diagnosed between 1979
and 1997 were analysed. The median age at
diagnosis was 9.2 yrs «1-41). The indication
for HOT was a primary metastatic disease (157
pts) or relapse/progression of a primary
localised tumour (261 pts). The first line
therapy was given for majority of patients
according to different European studies
between 1979 and 1997, Le. SlOP Studies,
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Italian (AIEOP, ICG) and German (CWS)
studies. 363 patients received one HOT, 50
double and 5 triple. 57 % of pts were in CR
before HOT, the remainder had a macroscopic
tumour mass. The proportion of patients alive
who received HOT in 1.CR (164) or 2.0R (74)
did not differ and was 36%. In the majority of
pts the HOT contained melphalan either alone
(23%) or in combination with etoposide,
carboplatin, cyclophosphamid, BCNU and
vincristin (47%). The median time from the last
event to the first HOT ranged between 8-9
months and did not differ dependent on the
indication for HOT. There was no major
difference at the outcome according to the
indication for HOT: 28% pts with primary
metastatic RMS are alive in comparison to
35% with other indications (relapse or primary
metastatic) for HOT. The rate of toxic death
was 9% and 5% respectively. There was a
difference in prognosis between primary
metastatic and other pts dependent on the
number of HOT. The best group with 41%
patients alive consisted of pts with a relapsed
or resistant disease with double HOT. In
contrast, pts who received double HOT
because of primary metastatic tumour had the
worst prognosis, only 11 % being alive.
Patients diagnosed between 1989 and 1997
had a significant better chance of survival:
38% vs. 14%, as compared with patients
diagnosed earlier, Le. in the period of 1979-
1988. The main reason for the better outcome
was the dramatical improvement in the rate of
fatal toxicities 16% vs. 2%.
What is interesting is the fact that the median
time from the last HOT to tumour-death was
very short 9 months in all pts. The difference
between pts in CR before HOT and those not
achieving a CR was only about 2 months. The
median time to toxic death was very short: 1,5
months. These data show that what one
considers as CR probably does not represent
a remission, and the growth dynamic of tumour
cells that survived HOC is very high. In
conclusion: patients with high risk RMS treated
in the last 10 years in different European
centers seem to have gained some benefit
from HOT. Since the progression of the
disease occured very quickly after HOT the
question aris~s it there is a negative selection
of very malignant clones or whether the
immundeficiency after HOT contributes to the
rapid growth of the residual tumour. Therefore,
it seems most likely that a some kind of
immunmodulation after HOT is needed.
The German Soft Tissue Sarcoma Study HO-
CWS 96 has compared the efficacy of double
HOT versus an oral maintanance therapy as a
consolidation therapy in patients with primary
metastatic rhabdomyosarcoma-like soft tissue
sarcoma [27]. High dose treatment consisted
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of a. tandem cycle of thiotepa (600 mg/m2) +
cyclophosphamide (4500 mg/m2) and
melphalan (120 mg/m2 ) + etoposide (1800
mg/m2). The maintanance therapy consisted of
trofosfamid (10 days 150 mg/m2/day) +
etoposide (10 days 50 mg/m2/day) and
trofosfamid (10 days 150 mg/2/d) + idarubicin
(4 x5 mg/m2/d). In the high dose group only
3/22 remained progression-free, whereas 6/11
orally treated patients.
These data showed that HOT in poor
prognosis rhabdomyosarcoma cannot be
regarded as an established therapy leading to
a better prognosis and should be performed in.
prospective controlled trials only.
WILMS' TUMOUR
The prognosis for pts with Wilms' tumour
even with a primary metastatic disease is very,
good so the experience with HOT is very
limited. There are, however, still primary
metastatic or recurrent tumours which cannot
be controlled by conventional chemotherapy.
Oallorso et al. have analysed pts with poor risk
Wilms' tumour registered in the EBMT registry:
81 received melphalan based HOT [28]. The
tumour status before HOT was very
heterogenous, CR, PR and even RR. The
overall disease-free survival from HOT was
57% and for pts in CR before HOT 78%.
The SFOP has conducted the first
prospective study trial on HOT for high-risk
relapsed Wilms' tumour. The EFS at 3 yrs was
50% [29]. So in conclusion: there is no
statistically proved benefit from HOT in Wilms'
tumour, but the EBMT and SFOP results are
sufficiently encouraging to warrant prospective
evaluation.
BRAIN TUMOURS
Brain tumours are the second most frequent
neoplasms in children. Oespite advances in
surgery, chemotherapy and radiotherapy, cure
rates for children with malignant brain tumours
remain modest. The prognosis for recurrent
brain tumours is dismal. The role of HOT in
brain tumours is based on the premise that
they are sensitive to alkylator-based
chemotherapy and show a steep dose-
response curve. Several studies have been
published in children with brain tumours who
received HOT as a salvage in a primary poor
risk or relapsed disease.
In 1996 Mahoney et al published the results
of a multicenter POG study for children with
recurrent or progressive brain tumors
(medulloblastoma, ependymoma, glioma,
PNET) [30]. The HOT consisted of increasing
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doses of cyclophosphamid administered
sequentially with melphalan. BM was given as
rescue: 19 children were enrolled on this
study. All these patients had been previously
treated with cranial or craniospinal
radiotherapy: 17 of 18 pts having measurable
disease at the time of HOT. There was a high
TRM: 22%. 39% pts achieved a complete
response, EFS at one 1yr was 39%.
In a multicentric study published by Graham
et al. 49 pts with recurrent or poor prognosis
brain tumours (medulloblastoma, glioblastoma,
ependymoma, germ cell, PNET) were treated
with HDT consisting of busulfan, melphalan,
carboplatin and etoposide [31]. BM was given
as rescue. Only one therapy related death was
noted and 18 pts were disease free at 22-55
months after HOT. It was concluded that some
pts may benefit from such an approach.
Gururangan et al. reported on 20 patients
with recurrent malignant brain tumours
(medulloblastoma, glioblastoma, PNET,
pinealoblastoma) treated with the HOT that
consisted of different combination of
carboplatin. thiotepa, etoposide, and
carmustine (BCNU). Autologous BM was used
as rescue. Twelve patients received
radiotherapy 6 weeks post-HOT. The EFS at 3
yrs was 47% [32]. Therapy related mortality
was 10%. This study shows that HOT followed
by RTX may be an effective therapy for some
chlidren with recurrent brain tumours.
The prospective assessment of HOT in
children with diffuse pontine gliomas has been
made by SFOP. HDT consisting of busulfan
and thiotepa was initiated 40-60 days after
radiotherapy: 36 pts were included in the
study. No benefit from this aggressive
treatment was seen [33].
CONCLUSIONS AND FUTURE
PERSPECTIVES
HDT improves the degree of tumour volume
reduction and consenquently prolongs EFS
and OS. There is no proved benefit of HOT for
cure rates. Since fatal toxicities have been
reduced by a better supportive care and the
use of highly purified HSC, the HOT can be
used in the future as a kind of consolidation
therapy, followed by maintenance therapies
such as stimulation of differentiation, anti-
angiogenesis, . or immunmodulation for
eradication of a microscopic disease. There
are still, however, a number of unanswered
questions with regard to HDT. The best
conditioning regimen has yet to be found.
Another question is whether there is a
preferred rescue product. Autologous
peripheral mobilized cells are now thought to
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be the best source of haematopoietic rescue.
PBSC produce more rapidengraftment than
-bone marrow, which in turn leads to decreased
toxicity of HOT. Nevertheless the question of
whether the purging of autologous grafts can
improve the outcome remains to be answered.
Based on the results of gene marking studies it
is now apparent that neuroblastoma cells
contaminating the grafts can contribute to
relapse. However, retrospective analyses have
not demonstrated a significant reduction in the
risk of relapse by purging. The contamination
with tumour cells remains, however, as a major
problem. The methodology of a positive
selection of CD34 positive cells has been
established. It is possible, however, that some
tumour cells do express C034 antigens, and,
as a result, are present in the C034 positive
products. The absence of a benefit from
allogeneic bone marrow transplantation
indicates that tumour contamination of the
autologous grafts did not contribute to large
number of relapses, and that alloreactive
cytotoxic T lymphocytes are not substantially
effective against solid tumous. Graft versus
tumour effects are well documented after
allogeneic transplantation for haematologic
malignancies. Oue to a major progress and
eVOlution in the field of allogeneic
transplantation allogeneic stem cells became
now a very interesting alternative as a therapy
modality in patients with solid tumours. There
is some evidence now that a graft vs. tumour
effect can be established.
A possible concept for the future could
employ conventional therapy with local therapy
as induction and consolidation with HDT and
stem cell rescue followed by tumour specific
peptide vaccination with autologous dendritic
and T cell transplantation or allogeneic cell
mediated therapy, Le. by induction of mixed
chimerism and anti-tumour effects.
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